Drug Type Universal CAR-T |
Synonyms Allogeneic GCC-CAR-T cell(Wondercel Biotech), Universal GCC-CAR-T cell(Wondercel Biotech), REVO-UWD-01 + [2] |
Target |
Action antagonists |
Mechanism GC-C antagonists(Heat-stable enterotoxin receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Colorectal Adenocarcinoma | Phase 1 | China | 23 Oct 2024 | |
| Colorectal Cancer | Phase 1 | China | 23 Oct 2024 | |
| Metastatic Colorectal Carcinoma | Phase 1 | China | 23 Oct 2024 | |
| Esophageal Carcinoma | Clinical | China | 01 Sep 2026 | |
| Stomach Cancer | Clinical | China | 01 Sep 2026 |





